Cargando…

Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea)

AIMS: To investigate the effectiveness of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors on the risk of progression to end‐stage renal disease (ESRD) and all‐cause mortality in a broad range of patients with type 2 diabetes (T2D) using a Korean nationwide cohort. MATERIALS AND METHODS: Using dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koh, Eun Sil, Han, Kyungdo, Nam, You‐Seon, Wittbrodt, Eric T., Fenici, Peter, Kosiborod, Mikhail N., Heerspink, Hiddo J. L., Yoo, Soon‐Jib, Kwon, Hyuk‐Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839503/ https://www.ncbi.nlm.nih.gov/pubmed/33118320 http://dx.doi.org/10.1111/dom.14239

Ejemplares similares

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
por: Real, Jordi, et al.
Publicado: (2021)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
por: Wittbrodt, Eric, et al.
Publicado: (2019)

SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education
por: Gunawan, Felona, et al.
Publicado: (2019)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?
por: Giorgino, Francesco, et al.
Publicado: (2020)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study
por: Lee, Joonyub, et al.
Publicado: (2023)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
por: Koh, Eun Sil, et al.
Publicado: (2023)

ODP544 Cumulative exposure of metabolic syndrome components and the risk of end-stage renal disease in the general population: a nationwide cohort study
por: Yoo, Soon Jib, et al.
Publicado: (2022)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
por: Dekkers, Claire C J, et al.
Publicado: (2018)

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
por: Kim, Mee Kyoung, et al.
Publicado: (2023)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

ODP189 Effects of Exercise Initiation and Smoking Cessation after New-Onset Type 2 Diabetes Mellitus on Risk of Mortality and Cardiovascular Outcomes
por: Yoo, Soon Jib, et al.
Publicado: (2022)

Blood glucose may be an alternative to cholesterol in CVD risk prediction charts
por: Braun, Julia, et al.
Publicado: (2013)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2
por: van der Hoek, Sjoukje, et al.
Publicado: (2021)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

High glucose and palmitate increases bone morphogenic protein 4 expression in human endothelial cells
por: Hong, Oak-Kee, et al.
Publicado: (2016)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_su12jk6oiqc3kfr9chnpl525vb